Objective: To estimate the genetic risk conferred by known amyotrophic lateral sclerosis (ALS)-associated genes to the pathogenesis of sporadic ALS (SALS) using variant allele frequencies combined with predicted variant pathogenicity.
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of the upper and lower motor neurons, which eventually leads to death within an average of 3-5 years 1 after symptom onset. ALS is classified as familial (FALS) when a clear family history of ALS exists and sporadic (SALS) when it does not. No clinical features reliably distinguish FALS from SALS. Genetic research on ALS has largely been focused on FALS, which represents 10% of ALS cases. 1 Most FALS is inherited in autosomal dominant fashion. However, this transmission pattern can be complicated by the early death of unrecognized affected family members due to non-ALS causes, misdiagnoses in older affected individuals, small family sizes, incomplete penetrance of genetic risk factors, and the development of disorders associated with ALS, such as frontotemporal dementia (FTD). Thus, sporadic and familial forms of ALS can be difficult to distinguish, and much remains unknown about the roles of genetic factors in FALS and especially in SALS.
The discovery of the pathogenic (G 4 C 2 ) n hexanucleotide repeat expansion of C9orf72 in a large percentage of FALS and SALS patients, [2] [3] [4] as well as the identification of other ALS genes in patients with SALS, 5, 6 has highlighted the importance of genetic risk factors in SALS pathogenesis. The significance of genetics in SALS is further supported by ALS genome-wide association studies, which estimate the heritability of ALS to be at least 21.0%. 7 With the growing affordability and availability of next-generation sequencing technologies, along with the advent of specific treatments for certain genetic forms of ALS, 8 it is increasingly important to understand the genetic factors in causing SALS. Currently, there is considerable variation in estimates of the percentage of SALS cases caused by genetic variants, ranging from 11% 5 to 28% 9 in populations of European ancestry. This variation is due largely to differences in estimation methods. In one large study, 9 the percentage was derived by calculating the portion of SALS cases with a rare (minor allele frequency [MAF] ,0.01), protein-altering variant in a set of known ALS genes. Using variant rarity as the main criterion for pathogenicity may have inflated the risk estimate as the majority of rare nonsynonymous variants are not thought to be pathogenic. 10 In this study, we sought to better estimate the percentage of SALS cases that have an identifiable genetic factor likely responsible for disease pathogenesis. To address this, a joint approach utilizing both allele frequency and variant pathogenicity prediction was used to determine the percentage of SALS cases that possess a potentially deleterious genetic variant in an ALS-associated gene.
METHODS Standard protocol approvals, registrations, and patient consents. The sample collection and study design we performed was approved by the University of Utah institutional review board. Written informed consent for diseasespecific genetic studies was obtained from each patient who participated in this study.
Participants. Patients with ALS diagnosed at the University of
Utah from 2011 to 2013 were invited to participate in genetic studies. All participants were seen by neuromuscular specialists and diagnosed with probable or definite ALS according to revised El Escorial criteria. 11 These patients were followed longitudinally in our motor neuron disease clinic. Patients with SALS were identified as having no self-reported family history of ALS, probable ALS, or FTD. In total, 96 patients with SALS were enrolled in this study. DNA was obtained from whole blood of each participant using the Gentra Puregene Blood Kit (Qiagen, Venlo, Netherlands).
Identification of deleterious ATXN2 and C9orf72 repeat expansions. ATXN2 CAG repeat size was determined by fluorescent PCR amplification. Repeat lengths between 29 and 33 were considered to be of intermediate length and deleterious. 12 The detection of C9orf72 GGGGCC repeat expansions was performed by using previously established repeat primed-PCR and amplicon length analysis criteria. 13 Whole exome sequencing. Patient Quality control. Utah's population is outbred and genetically resembles other populations of northern European ancestry.
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As a result, we focused our analysis on patients with SALS who were of European ancestry in order to limit population stratification effects. Patient ancestry derived from genetic data is more reliable than self-reported ancestry, which has been used in previous ALS studies. 9, 18 An Admixture 19 analysis (K 5 3) was performed to determine the genetic ancestry of each patient with SALS. Any participants with less than 90% European ancestry were removed from further analysis. Next, principal components analysis (PCA) was performed using smartpca 20 to remove poorquality samples. Any sample with an eigenvector value more than 6 SDs from the mean for the first 10 principal components was discarded. Finally, the sex of each patient with SALS was inferred by PLINK 1.9 21 and compared to the reported sex to identify sample identification errors.
Variant annotation. SnpEff 22 (v4.1) was used to identify protein-coding and splice-site altering genetic variants. These variants were then annotated with information from the database for nonsynonymous single nucleotide polymorphism functional predictions (dbNSFP; sites.google.com/site/jpopgen/dbNSFP) v2.9.
23 dbNSFP contains 11 different in silico functional prediction methods that determine which single nucleotide variants (SNVs) are likely to alter protein function. MetaSVM was chosen as the primary method to determine variant pathogenicity as it has been shown to have a better predictive ability than other methods. 24 Insertion, deletion, and splice-site acceptor/donor variants were classified as deleterious. Variants were also annotated with European-specific MAF estimates from the Exome Aggregation Consortium (ExAC) 25 by dbNSFP. A manual search of the Amyotrophic Lateral Sclerosis Online Database (ALSoD), 26 the Single Nucleotide Polymorphism database (dbSNP), 27 and the Human Gene Mutation Database (HGMD) 28 was performed to identify known ALS pathogenic variants.
Genetic risk analysis. To determine the proportion of patients
with SALS who have a potentially disease-causing variant in a SALS gene, all annotated rare (European MAF ,0.001), protein-coding, and splice-site altering variants in 31 ALSassociated genes (ANG, CHCHD10, CHMP2B, DAO, DCTN1, ELP3, ERBB4, EWSR1, FIG4, FUS, GLE1, GRN, HNRNPA1, HNRNPA2B1, MATR3, NEFH, NEK1, OPTN, PFN1, SETX, SOD1, SPAST, SQSTM1, SS18L1, TAF15, TARDBP, TBK1, TUBA4A, UBQLN2, VAPB, VCP) were assessed. A MAF of 0.001 corresponds roughly to the European allele frequency of SOD1:p.Asp91Ala, 29 which is the most common known pathogenic variant we could identify in ALSoD. The proportion of patients with SALS who possessed a rare and deleterious variant, as determined by MetaSVM, in at least 1 of the 31 ALS-associated genes or had a deleterious repeat expansion in C9orf72 or ATXN2 was then calculated. The proportion of patients with SALS who possessed a rare variant, deleterious or not, or a repeat expansion in an ALS-associated gene was also calculated as a reference. All variants were assumed to act in a dominant fashion, like most ALS-causing variants. 30 Odds ratio analysis. Genetic burden analysis determines if there is a difference in the amount of pathogenic variation, or burden, in a set of genes between cases and controls. To determine whether the combination of variant frequency and MetaSVM predictions identified variant pathogenicity better than variant frequency alone, we estimated the excess burden of ALSassociated genes in SALS cases vs healthy controls. To do so, whole exome sequence data from 714 individuals from 181 families of the Simons Simplex Collection (SSC) 31 were analyzed. The SSC dataset contains exome sequence data from children with autism, an unaffected sibling, and their unaffected parents. These samples underwent joint variant calling with the SALS exomes using the same pipeline as described above. Admixture and PCA were performed as previously described on 362 unaffected parents to select for high-quality controls of European ancestry. Variant calls were limited to exome capture regions with at least 53 coverage on average in both the SALS and SSC cohorts. The proportion of SSC controls with a rare and deleterious variant in at least 1 of the same 31 ALS-associated genes was calculated. An odds ratio (OR) analysis was then performed to determine whether the burden of ALS-associated genes is higher in patients with SALS than in normal controls. An OR analysis comparing the genetic burden when only variant frequency was utilized was also performed. The significance of this OR was determined by a one-tailed Fisher exact test.
RESULTS Patient cohort characteristics. The Admixture (figure 1A) and PCA (figure 1B) results showed that 9 of the 96 patients with SALS possessed significant non-European ancestry or were genetic outliers. No sex mismatches were detected in the data. The 87 patients with SALS of European ancestry were selected for analysis, and characteristics of these patients are detailed in table 1. We selected 324 SSC parents as high-quality European controls because Admixture showed that 38 of the parents were likely non-European.
Known ALS-associated genetic variants. We identified pathogenic C9orf72 hexanucleotide repeat expansions in 5 of 87 patients with SALS (5.7%). Two patients with SALS (2.3%) possessed ALS-associated trinucleotide repeat expansions in ATXN2 (31 and 32 repeats in length, respectively). We compared the rare (European MAF ,0.001) coding variants in 31 ALSassociated genes uncovered in the SALS cohort to known ALS risk variants contained in ALSoD, dbSNP, and HGMD. This comparison revealed only one known ALS-associated rare SNV (SOD1:p.Asp91Ala 29 ), which was found in 2 heterozygous patients (table 2). Potentially novel ALS variants. After examining the 31 ALS-associated genes in our patient cohort, we identified 18 rare coding variants (European MAF ,0.001) not previously described in ALS (table 2) . Of these variants, 10 were not found in dbSNP (v141). Furthermore, 6 were novel, as they were not found in ExAC, the 1000 Genomes Project dataset, 15 or the National Heart, Lung, and Blood Institute Exome Sequencing Project dataset.
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These 28 rare variants were used to calculate the proportion of patients with SALS who have a rare mutation in at least one ALS-associated gene. A total of 25 patients with SALS (28.7%) had at least one DISCUSSION We report findings from a genomic analysis of 87 patients with SALS of European origin. In total, 28 rare variants were found in 33 ALS genes in our patient cohort. Only one non-repeat variant that has been previously described in ALS pathogenesis was observed (SOD1:p.Asp91Ala). This variant is known to cause autosomal recessive ALS and was predicted to be deleterious by MetaSVM. SOD1: p.Asp91Ala has also been suggested to act in a dominant fashion; however, few instances of this have been reported. 32 In addition, we identified 18 rare variants in ALS-associated genes that have not been described previously in patients with ALS. Of these 18 variants, 5 either caused a protein loss of function or were predicted to be deleterious by MetaSVM. One is a frameshift variant in the ubiquitin-associated domain of SQSTM1. This change likely ablates SQSTM1's ability to bind ubiquitinated substrates, which is often seen in SQSTM1 variants that cause ALS.
33 NEK1:c.1750-1G.A is a novel loss of function SNV that ablates the splice acceptor site of intron 19, which is located approximately in the middle of the gene. NEK1:p.Gly646Arg is another damaging variant that was discovered in NEK1; however, it does not occur in a defined protein domain. FUS:p. Gly465Glu is predicted to be damaging by MetaSVM and affects an amino acid one position upstream from previously reported SALS variant (FUS:p.Met464Ile).
34 ERBB4:p.Gly735Val is an SNV predicted to be deleterious and occurs in the Abbreviations: CI 5 confidence interval; MAF 5 minor allele frequency; SSC 5 Simons Simplex Collection. The incorporation of MetaSVM predictions of deleteriousness shows a much higher genetic burden of ALS-associated genes in patients with SALS than by considering variant rarity alone.
tyrosine kinase domain of erbB-4. The tyrosine kinase function of erbB-4 is required for protein autophosphorylation and triggering downstream signaling cascades upon activation. A variant in the tyrosine kinase domain of erbB-4, which was identified from a FALS family, has been shown to reduce protein autophosphorylation and likely causes ALS. 35 Additional studies will determine the functional importance of these variants on cellular and molecular mechanisms.
We have demonstrated that using variant pathogenicity predictions is more reliable than variant frequency alone to determine the proportion of patients with SALS whose disease is likely caused by a variant in an ALS-associated gene. The relative effect of ALS-associated genes is stronger when variant pathogenicity is considered instead of only variant rarity. This follows from the fact that an appreciable proportion of rare nonsynonymous variants are not predicted to be functionally damaging. 10 Thus, only a subset of rare variants in ALS-associated genes are pathogenic.
Our approach to estimating the genetic contribution of a large panel of known ALS-associated genes by directly predicting variant pathogenicity differs from earlier approaches. The first attempts at determining the proportion of genetically caused SALS cases did so by calculating the proportion of patients who had a protein-coding variant in a panel of 5-7 ALS-associated genes. 18, [36] [37] [38] These analyses yielded estimates ranging from 2.8% to 11%, which are lower than our estimate of 17.2%. A more recent study, in which variant rarity (MAF ,1%) was used as the sole criterion for pathogenicity in a panel of 17 ALS-associated genes, concluded that genetic factors may cause 27.8% of SALS cases, 9 a figure similar to our estimate when only variant rarity is considered (table e-1). However, these variants (MAF ,1%) are not significantly more common in our patients with SALS than in unaffected controls (OR 1.25, p . 0.25), suggesting that many of them are not pathogenic. The same 17 ALS-associated genes are significantly more burdened in patients with SALS than controls when variant rarity (MAF ,1%) and pathogenicity (estimated by MetaSVM) are combined (OR 2.61, p , 0.02). These OR differences support our conclusion that variant frequency alone is not a sufficient predictor of SALS risk.
Another analysis of 33 ALS-associated genes defined only novel and extremely rare variants (MAF z 0.0002) as pathogenic and found that 14.5% of SALS cases could be attributed to genetic causes. 39 In our sample, the genetic burden of ALSassociated genes in patients with SALS is less when pathogenicity is defined in the same way than when MetaSVM is integrated (OR 2.24, p , 0.01 vs OR 5.52, p , 2 3 10 24 ). These results demonstrate that direct predictions of variant pathogenicity are important for defining genetic risk in SALS and other genetic diseases.
Our results also highlight that genetic factors play an important role in the disease, the clinical relevance of which will become even more important as genetic specific treatments become available. Further, exome or targeted sequencing of patients with SALS and their family members is likely warranted to provide adequate genetic counseling. In addition, our results suggest the distinction between SALS and FALS may be problematic as heritable risk factors are found in a significant proportion of patients with SALS. Future genetic investigations of patients with SALS are needed to broaden the scope of SALS-associated loci. Studies with larger patient cohorts that incorporate measures of variant pathogenicity will also be needed to further pinpoint the proportion of SALS cases with an identifiable probable genetic cause of disease, especially as more ALS-associated genetic loci are discovered.
Our study has several limitations. First, the size of the SALS cohort was limited, especially given the genetically heterogeneous nature of ALS. Second, because we focused on individuals of European ancestry, our findings may not be completely applicable to ALS found in other populations. Third, 13 of the 324 (4.0%) healthy control samples used in this study had at least one rare and deleterious variant in ALSassociated genes as predicted by MetaSVM (table 3;  table e-3) . The mean age of these individuals was 41.76 (SD 5.92) years, which is much lower than the average age at onset of SALS at 56 years of age. 40 It is possible that some of the control individuals with these variants could develop ALS later in life.
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